EPO Receptor Agonist Improves Glucose Tolerance in Diabetic Mice
Author Information
Author(s): Michael S. Scully, Tatiana A. Ort, Ian E. James, Peter J. Bugelski, Dorie A. Makropoulos, Heather A. Deutsch, Elsbet J. Pieterman, Anita M. van den Hoek, Louis M. Havekes, William H. duBell, Joshua D. Wertheimer, Kristen M. Picha
Primary Institution: Centocor R&D Inc.
Hypothesis
Can CNTO 530, a novel EPO receptor agonist, improve glucose tolerance and insulin sensitivity in diabetic mice?
Conclusion
CNTO 530 significantly improves glucose tolerance and insulin sensitivity in diet-induced obese mice.
Supporting Evidence
- CNTO 530 reduced the area under the curve in glucose tolerance tests.
- HOMA analysis indicated improved insulin sensitivity.
- Glucose uptake in skeletal muscle and heart was increased in treated mice.
Takeaway
A new drug called CNTO 530 helps mice with diabetes use sugar better, which could help people with diabetes too.
Methodology
The study involved administering CNTO 530 to diabetic mice and measuring glucose tolerance and insulin sensitivity through various tests.
Limitations
The study was conducted on mice, and results may not directly translate to humans.
Participant Demographics
C57Bl/6J mice, diet-induced obesity model.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website